Advertisement
Clinical Therapeutics
Advanced searchSave search
Research Article| Volume 24, ISSUE 3, P417-433, March 2002

Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: A randomized, double-blind, placebo-controlled clinical trial

DOI:https://doi.org/10.1016/S0149-2918(02)85043-3
Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: A randomized, double-blind, placebo-controlled clinical trial
Previous ArticleRandomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model
Next ArticleSafety and local tolerability of intramuscularly administered ertapenem diluted in lidocaine: A prospective, randomized, double-blind study versus intramuscular ceftriaxone
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Background: Because the symptoms of premenstrual dysphoric disorder (PMDD) are limited to the luteal phase of the menstrual cycle, the potential benefit of luteal-phase dosing has been hypothesized.
      Objective: This multicenter, randomized, double-blind, placebo-controlled, parallel-group trial evaluated the efficacy and tolerability of enteric-coated fluoxetine 90 mg given once or twice during the luteal phase for the treatment of PMDD.
      Methods: Study drug was given 14 and 7 days before expected menses during the luteal phase of 3 menstrual cycles. After a screening period and single-blind placebo lead-in period, eligible women were randomized to 1 of 3 treatment groups: enteric-coated fluoxetine 90 mg on both days (LPWD×2); placebo 14 days before menses and enteric-coated fluoxetine 90 mg 7 days before menses (LPWD×1); or placebo on both days (PLC). The primary efficacy measure was change from baseline in mean luteal-phase scores on the Daily Record of Severity of Problems (DRSP). Secondary efficacy measures included scores on the Rating Scale for Premenstrual Tension Syndrome, Clinician-Rated (PMTS-C); the Clinical Global Impression (CGI)—Severity scale; and the Patient Global Impression (PGI)—Improvement scale. Quality of life was assessed using the Sheehan Disability Scale.
      Results: Two hundred fifty-seven women were randomized to treatment. At the end of the study, the LPWD×2 group had statistically significant improvements in DRSP total, DRSP mood subtotal, DRSP social functioning subtotal, PMTS-C, CGI-Severity, PGI-Improvement, and Sheehan Disability Scale work and family life scores compared with LPWD×1 and PLC (each measure, P < 0.05). There was also a statistically significant improvement in the score on the social life section of the Sheehan Disability Scale with LPWD×2 compared with PLC (P = 0.037). Across all treatment groups, 5 patients discontinued due to nonserious adverse events. Rates of discontinuation for any reason did not differ between the 3 treatment groups.
      Conclusion: The findings of this study support the efficacy and tolerability of enteric-coated fluoxetine 90 mg given twice during the luteal phase of the menstrual cycle for the treatment of PMDD.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Johnson SR
        The epidemiology and social impact of premenstrual symptoms.
        Clin Obstet Gynecol. 1987; 30: 367-376
        • Rivera-Tovar AD
        • Frank E
        Late luteal phase dysphoric disorder in young women.
        Am J Psychiatry. 1990; 147: 1634-1636
        • Ramcharan S
        • Love EJ
        • Fick GH
        • Goldfien A
        The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: Attributable risk and risk factors.
        J Clin Epidemiol. 1992; 45: 377-392
        • American Psychiatric Association
        Fourth Edition. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association, Washington, DC1994
        • Endicott J
        • Amsterdam J
        • Eriksson E
        • et al.
        Is premenstrual dysphoric disorder a distinct clinical disorder?.
        J Women's Health. 1999; 8: 663-679
        • Yonkers KA
        • Halbreich U
        • Freeman E
        • et al.
        • Sertraline Premenstrual Dysphoric Collaborative Study Group
        Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial.
        JAMA. 1997; 278: 983-988
        • Steiner M
        • Steinberg S
        • Stewart D
        • et al.
        • Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group
        Fluoxetine in the treatment of premenstrual dysphoria.
        N Engl J Med. 1995; 332: 1529-1534
        • Su TP
        • Schmidt PJ
        • Danaceau MA
        • et al.
        Fluoxetine in the treatment of premenstrual dysphoria.
        Neuropsychopharmacology. 1997; 16: 346-356
        • Pearlstein TB
        • Stone AB
        Long-term fluoxetine treatment of late luteal phase dysphoric disorder.
        J Clin Psychiatry. 1994; 55: 332-335
        • Freeman EW
        • Rickels K
        • Arredondo E
        • et al.
        Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant.
        J Clin Psychopharmacol. 1999; 19: 3-8
      11. FDA approves fluoxetine to treat premenstrual dysphoric disorder.
        FDA Talk Paper T00-31. July 6, 2000; (Available at: http://www.fda.gov/bbs/topics/ANSWERS/ANS01024.html. Accessed November 6, 2001)
        • Steiner M
        • Korzekwa M
        • Lamont J
        • Wilkins A
        Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria.
        Psychopharmacol Bull. 1997; 33: 771-774
        • Judge R
        • Brown E
        • Miner C
        • Dillon J
        Intermittent fluoxetine dosing in premenstrual dysphoric disorder.
        World J Biol Psychiatry. 2001; 2 (Abstract): 204S
        • Sundblad C
        • Wikander I
        • Andersch B
        • Eriksson E
        A naturalistic study of paroxetine in premenstrual syndrome: Efficacy and side-effects during ten cycles of treatment.
        Eur Neuropsychopharmacol. 1997; 7: 201-206
        • Wikander I
        • Sundblad C
        • Andersch B
        • et al.
        Citalopram in premenstrual dysphoria: Is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?.
        J Clin Psychopharmacol. 1998; 18: 390-398
        • Jermain DM
        • Preece CK
        • Sykes RL
        • et al.
        Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study.
        Arch Fam Med. 1999; 8: 328-332
        • Young SA
        • Hurt PH
        • Benedek DM
        • Howard RS
        Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: A randomized, double-blind, placebo-controlled crossover trial.
        J Clin Psychiatry. 1998; 59: 76-80
        • Halbreich U
        • Smoller JW
        Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome.
        J Clin Psychiatry. 1997; 58: 399-402
        • Schmidt ME
        • Fava M
        • Robinson JM
        • Judge R
        The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder.
        J Clin Psychiatry. 2000; 61: 851-857
        • Endicott J
        • Harrison W
        Daily rating of severity of problems form. Dept of Research Assessment and Training, NY State Psychiatric Institute, New York1990
        • Steiner M
        • Streiner DL
        • Steinberg S
        • et al.
        The measurement of premenstrual mood symptoms.
        J Affective Disord. 1999; 53: 269-273
      22. Guy W ECDEU Assessment Manual for Psychopharmacology, Revised. National Institute of Mental Health, Rockville, MD1976: 76-338
        • Steiner M
        • Haskett RF
        • Carroll BJ
        Premenstrual tension syndrome: The development of research diagnostic criteria and new rating scales.
        Acta Psychiatr Scand. 1980; 62: 177-190
        • Leon AC
        • Olfson M
        • Portera L
        • et al.
        Assessing psychiatric impairment in primary care with the Sheehan Disability Scale.
        Int J Psychiatry Med. 1997; 27: 93-105
        • Montgomery DC
        Design and Analysis of Experiments. John Wiley & Sons, New York1991: 50-94
        • Steiner M
        • Romano SJ
        • Babcock S
        • et al.
        The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder.
        Br J Obstet Gynaecol. 2001; 108: 462-468

      Article info

      Publication history

      Accepted: January 9, 2002

      Identification

      DOI: https://doi.org/10.1016/S0149-2918(02)85043-3

      Copyright

      © 2002 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX